Incyte (INCY) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
Incyte (INCY) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 93.06% |
| Mar 31, 2026 | 1.35% |
| Dec 31, 2025 | -29.44% |
| Sep 30, 2025 | 4.73% |
| Jun 30, 2025 | 156.00% |
| Mar 31, 2025 | -21.37% |
| Dec 31, 2024 | 89.01% |
| Sep 30, 2024 | 123.94% |
| Jun 30, 2024 | -362.23% |
| Mar 31, 2024 | -15.68% |
| Dec 31, 2023 | 17.41% |
| Sep 30, 2023 | -15.86% |
| Jun 30, 2023 | 837.88% |
| Mar 31, 2023 | -23.74% |
| Dec 31, 2022 | -74.76% |
| Sep 30, 2022 | -30.14% |
| Jun 30, 2022 | 324.91% |
| Mar 31, 2022 | -93.26% |
| Dec 31, 2021 | 210.25% |
| Sep 30, 2021 | 21.60% |